EP0725580A1 - Fluid filled insole - Google Patents
Fluid filled insoleInfo
- Publication number
- EP0725580A1 EP0725580A1 EP94914349A EP94914349A EP0725580A1 EP 0725580 A1 EP0725580 A1 EP 0725580A1 EP 94914349 A EP94914349 A EP 94914349A EP 94914349 A EP94914349 A EP 94914349A EP 0725580 A1 EP0725580 A1 EP 0725580A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bladder
- metatarsal
- flow
- region
- heel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A43—FOOTWEAR
- A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
- A43B7/00—Footwear with health or hygienic arrangements
- A43B7/14—Footwear with health or hygienic arrangements with foot-supporting parts
- A43B7/1405—Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form
- A43B7/1455—Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form with special properties
- A43B7/147—Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form with special properties for sick or disabled persons, e.g. persons having osteoarthritis or diabetes
-
- A—HUMAN NECESSITIES
- A43—FOOTWEAR
- A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
- A43B17/00—Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined
- A43B17/02—Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined wedge-like or resilient
- A43B17/026—Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined wedge-like or resilient filled with a non-compressible fluid, e.g. gel, water
-
- A—HUMAN NECESSITIES
- A43—FOOTWEAR
- A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
- A43B17/00—Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined
- A43B17/02—Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined wedge-like or resilient
- A43B17/03—Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined wedge-like or resilient filled with a gas, e.g. air
- A43B17/035—Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined wedge-like or resilient filled with a gas, e.g. air provided with a pump or valve
Definitions
- the present invention is directed to fluid filled podiatric insoles, and more particularly to insole bladders having fluid flow directing and restricting members within the bladder.
- Fluid filled insoles have long been known in the art, see for example, U.S. Patent No. 4,567,677 to James Zona, U.S. Patent No. 4,115,934 to Hall and U.S. Design Patent No. D246.486 to John W. Nickel.
- Prior art insoles commonly comprise a bladder having an upper layer and a lower layer. The two layers are welded together at their marginal periphery.
- the bladder has a planar, foot-shaped configuration, which includes a metatarsal region, a heel region, and an arch region there between.
- the bladder is filled with a fluid, e.g., water, air, gel or a combination thereof.
- a fluid e.g., water, air, gel or a combination thereof.
- the benefits of fluid filled insoles are well known. These benefits include cushioning of the feet and massaging action on the plantar surface of the feet due to movement of the fluid within the bladder.
- the fluid filled insoles of the prior art have not been entirely satisfactory, however, especially in the area of providing demonstrative medical benefits.
- Some prior insoles have little or no means for regulating the rate of fluid flow within the insole.
- the user's weight is initially applied to heel, and then is transferred to the ball of the foot. This causes the fluid within the bladder to move, respectively, from the heel region to the metatarsal region and then back towards the heel again. Without means for regulating fluid flow within the bladder, the fluid will rapidly surge or splash forward and back, adversely striking the plantar surface of the foot.
- Some prior art devices such as the insole of the Zona patent, have attempted to regulate flow from the heel region to metatarsal region and vice versa by placing flow restricting means in the arch area of the bladder. These flow restricting devices are only partly effective, however, as they do not regulate or direct the flow within the metatarsal or heel regions of the bladder. The location, direction, quantity and duration of fluid flow are important to achieve good massaging action on the foot, weight pressure distribution and directional stability.
- Some prior art insoles as shown for example in the Hall or Nickel patents have attempted to regulate fluid flow within the metatarsal and heel regions.
- the insole of the invention comprises a fluid tight bladder having an upper layer of flexible material and a lower layer of flexible material sealingly joined together at their peripheral margins.
- the bladder has a generally foot shaped planar configuration, with a metatarsal region, a heel region, and an arch region there between.
- the bladder is filled with a large molecular, hygroscopic, sterile liquid, preferably a mixture of polyvalent alcohol and distilled water.
- a plurality of flow deflectors preferably three, spaced transversely one from the other, and spaced from the medial and lateral margins of the bladder.
- the flow deflectors comprise weld points joining the upper and lower bladder layers.
- Substantially longitudinal flow channels are formed between the flow deflectors and between the flow deflectors and medial and lateral margins of the bladder.
- a plurality, preferably two, flow deflectors are located in the heel region of said bladder.
- One heel flow channel is formed between the heel flow deflectors.
- the bladder is filled with a large molecular, hygroscopic, sterile liquid, preferably a mixture of polyvalent alcohol and distilled water.
- a mixture of polyvalent alcohol and distilled water is sterile, non-toxic and resistant to contamination by bacteria or other microorganisms. Further, it has been found that the mixture of polyvalent alcohol and distilled water is not susceptible to evaporation or diffusion through the bladder layers. It is also autoclavable. In the event of a bladder puncture, the liquid may be easily removed from clothing and footwear, as the mixture is relatively non- greasy.
- the insole of the invention has been tested and found to provide several desirable medical and therapeutic benefits.
- the insole distributes the user's weight over a larger area thereby reducing the pressure exerted on the plantar surface of the user's foot.
- the reduction in pressure relieves stress on the bones of the foot that can cause foot pain, hard skin and in extreme situations, ulceration.
- the controlled flow of fluid through the bladder across the plantar surface of the user's foot during normal body movements provides a therapeutic massaging action.
- the massaging action improves venous pump function increasing blood circulation, which in turn improves transport of oxygen and nutrients to the cells in the foot and removal of waste products excreted from the cells.
- Improved blood circulation reduces the amounts of milk acid, thereby reducing the occurrence of myasthenia ("tired muscles").
- Zone therapy is a healing art involving stimulating specific reflex zones on the foot, resulting in beneficial effects on various internal organs.
- Fig. 1 is a plan view of a first preferred embodiment of the liquid insole of the invention.
- Fig. 2 is a cross-sectional view of the first embodiment of the invention taken along line 2-2 of Fig. 1.
- Fig. 3 is a cross sectional view of the first embodiment of the invention taken along line 3-3 of
- Fig. 1 is a plan view of a second embodiment of the invention.
- Fig. 5 is a plan view of a third embodiment of the invention.
- Fig. 6 is a plan view of the fourth embodiment of the invention.
- Fig. 7 is a plan view of a fifth embodiment of the invention.
- Fig. 8 is a plan view of a sixth embodiment of the invention.
- Fig. 9 is a plan view of a seventh embodiment of the invention.
- Fig. 10 is a cross-sectional view of the seventh embodiment of the invention taken along line
- the insole comprises a bladder 10 having an upper layer 12 and a lower layer 14.
- the insole preferably further includes a layer of velour material 16 substantially covering and laminated to the outer surface of upper bladder layer 14.
- the bladder layers 12 and 14 are sealing joined at their peripheral margins 18.
- the inner or medial peripheral margin is numbered 20 and the outer or lateral peripheral margin is numbered 22.
- the bladder comprises three main regions, namely a metatarsal region 24, a heel region 26 and an arch region 28 there between.
- the insole of the invention also includes a toe region 30 formed by a forward extension of bladder layers 12 and 14.
- the interior cavity 32 of the bladder 10 is filled with a sterile, non-toxic fluid.
- the fluid is preferably a mixture of large molecular, hygroscopic polyvalent alcohol (e.g. glycol) and distilled water, as is more fully described below.
- the fluid may freely flow between and throughout the metatarsal, arch, and heel regions.
- the toe region preferably does not contain fluid, because no significant part of the user's body weight rests on the toes.
- Within the metatarsal region 28 of bladder 22 there are a plurality of transversely spaced flow deflectors 34. Preferably, there are three metatarsal flow deflectors 34, but, one could employ two, four or more metatarsal flow deflectors.
- the spacing between each of the flow deflectors and between the flow deflectors and the medial and lateral peripheral margins of the bladder is substantially equal distance, and the flow deflectors are arranged in an arch, the convex side of which faces in a distal direction.
- the flow deflectors 34 are formed by weld points joining the upper bladder layer 12 to the lower bladder layer 14. Formation of flow deflectors by welding points joining the bladder layers improves the structural integrity of the bladder, improving durability.
- flow deflectors 34 Between flow deflectors 34 are flow channels 36 through which fluid flows during use of the insole. Additional flow channels 38 are also formed in the metatarsal region between flow deflectors 34 and the medial peripheral margin 20, and between flow deflectors 34 and the lateral peripheral margin 22.
- the metatarsal flow channels 36 and 38 extend in a generally longitudinal direction.
- Flow deflectors 34 are shown as being circular, but other shapes may be alternatively used.
- the heel region 26 of bladder 10 there are a plurality of flow deflectors 40. Because the heel region is a smaller area than the metatarsal region, two flow deflectors are preferably used. Alternatively, three or more could be used.
- the heel flow deflectors 40 are formed in the same manner as the metatarsal flow deflectors, by a weld point joining the upper and lower bladder layers 12 and 14. At least one generally longitudinal flow channels 42 is formed between heel flow deflectors 40. Additional heel flow channels 44 are formed between heel deflectors 40 and the medical and lateral peripheral margins of the bladder.
- Fig. 1 shows an elongated weld line 48 on the medial side of the bladder and a smaller weld point 50 on the lateral side of the arch region. A somewhat restricted, central flow channel 52 is formed there between. Side flow channels 54 are formed between the flow restrictors 46 and the peripheral margins 18 of bladder 10.
- the second through sixth embodiments of the fluid filled insole of the invention, Figs. 4 through 8, are identical in all respects except that alternative flow restrictors in the arch region 28 of the bladder are employed.
- the second embodiment of the invention, illustrated in Fig. 4 shows a flow restrictor comprising three weld points 56 joining the upper and lower bladder layers. Arch flow channels 58 are formed between the weld points.
- Fig. 5 shows the third embodiment of the insole of the invention.
- the flow restrictor in the arch region comprises a multiplicity of weld points 60 arranged in a diagonal arc.
- Plural flow channels 62 are formed between the weld points.
- Fig. 6 illustrates a fourth embodiment of the fluid filled insole of the invention.
- the fourth embodiment is characterized by a multiplicity of weld points 64 arranged in a straight, diagonal line, plus a lone weld point 66 spaced transversely from the others.
- Arch flow channels 68 are formed between the weld points.
- Figures 7 and 8 illustrate, respectively, fifth and sixth embodiments of the fluid filled insole of the invention.
- the fifth embodiment has an arch flow restrictor comprising a single "C" shaped weld 70, between the upper and lower bladder layers, forming adjacent flow channel 72.
- the sixth embodiment has an arch flow restrictor comprising two "C" shaped welds 74 forming an interior flow channel 76.
- Fig. 9 and 10 illustrate a seventh embodiment of the invention.
- the seventh embodiment is similar to the fifth embodiment, Fig. 7, except for the construction of the heel region, which comprises a shock absorbing foam material, as opposed to a liquid filled bladder.
- the seventh embodiment comprises a bladder 10 having an upper layer 12 and a lower layer 14.
- a layer of velour material 16 is laminated to the outer surface of the upper layer 14.
- the bladder 10 has a liquid filled metatarsal region 24 and arch region 28.
- the metatarsal region 24 includes transversely spaced flow deflectors 34 and longitudinal flow channels 36 and 38 as described above.
- the arch region 28 includes a flow restrictor 70 and flow passage 72.
- the insole further comprises a heel region 26 and a toe region 30, but these latter two regions are not liquid filled. Rather toe region 30 is unfilled and heel region 26 is filled with shock absorbing foam cushion 78.
- a barrier wall 80 separates the liquid filled regions 24 and 28 from the heel region 26 and prevents liquid from flowing from the
- the bladder is preferably fabricated from polyurethane sheet although polyvinyl chloride may also be used.
- the thickness of each bladder layer should be from about 600 to 800 micrometers, 600 micrometers being preferred.
- the velour material is preferably about 250 micrometers in thickness.
- the bladder may be formed by conventional friction welding techniques. Other welding techniques, such as thermal welding may be used alternatively.
- the bladder is filled with the liquid mixture leaving an opening in the peripheral weld, through which liquid may be introduced, then sealing the opening.
- the insole of the invention may be made and sold as an insole for removable placement in shoes by the user. Also, the insole may be built into footwear as a permanent feature.
- the fluid used to till the cavity 32 of the bladder 10 is a mixture of distilled water and a sterile, non-toxic, large molecular, hygroscopic liquid to prevent evaporation or diffusion through the bladder. Polyvalent alcohols, such as giycerol are preferred.
- One suitable formulation comprises approximately 60-70% polyvalent alcohol and approximately 30-40% distilled water. By using this mixture in lieu of plain water, improved benefits are achieved:
- the mixture of the invention as compared to water has a lower tendency to evaporate or diffuse through the bladder layers, thereby significantly improving life and durability of the insole.
- the liquid can withstand autoclaving as may be required by health care institutions.
- the insoles can be used in temperature ranges from minus 20 degrees Celsius to plus 120 degrees Celsius, because both the liquid mixture and bladder materials can withstand these temperature extremes.
- the liquid is fully sterile and non-toxic.
- the sterility of the liquid is extremely important for several reasons. Children, people and animals could eat the insole, possibly drinking or swallowing the liquid. Water becomes septic after a few months of storage in some insoles, because bacteria will grow and flourish in the water.
- the mixture of polyvalent alcohol and distilled water has a significantly higher density. This causes an improvement in the effects on the user's foot when wearing the insoles, because it helps to distribute the user's weight over a comparably larger area, and the slow movement of the vicious liquid will enhance the massage action.
- the liquid is relatively non-greasy. Thus, if the insoles are punctured or for any reason the liquid runs out into the user's socks or shoes, the shoes and socks may be readily cleaned. Testing has shown that there are four basic beneficial effects from wearing the insoles of the invention, namely: (1) reducing weight pressure on the foot; (2) stimulating blood circulation; (3) symmetric walking; and (4) zone therapeutic effect. Each of these therapeutic benefits will be explained in turn.
- the veins have a special venous pump system built-in that eases the transport of the blood back to the heart.
- the venous pump system functions in cooperation with the muscle activity since the moving muscle cause the veins to stretch and contract. Since the veins internally are equipped with venevalves (flaps) that prevent the blood from flowing away from the heart, the muscle activity on the veins causes the veins to function as a pump system that significantly increase blood transportation back to the heart.
- the foot muscles When an individual is standing or walking for more than four hours per day, the foot muscles may receive insufficient movement and exercise. Individual movement of the many small muscles in the foot is hindered. If the foot muscles have insufficient strength, they do not have the sustaining strength to maintain the weight of the body, and the heel bone and metatarsal bones may sink downwardly.
- the following chain reaction occurs:
- the foot muscles do not receive sufficient oxygen and carbohydrate quantities for maintaining adequate energy production and oxidation.
- Milk acid causes tiredness, heavy legs, and later pain, depending on the length of time walking or standing.
- the tiredness feeling tends to cause people to place themselves in inappropriate or awkward positions in an effort to remedy the feeling, again affecting other muscles, leading to pain in legs, back, head, etc.
- the movement of the liquid within the bladder will result in the user's body weight being distributed over a larger area; thus relieving pressure on the foot muscles and avoiding the above chain reaction.
- Tests reveal that the insole of the invention reduces the average pressure in kilograms per square centimeter against the plantar surface of the user's foot.
- the improved spreading of the user's weight is particularly applicable during standing or walking. It is important to avoid a high pressure on heel and metatarsal bones, since such pressure can cause foot pain, hard skin, and, in extreme situations, ulceration.
- the weight of the user pressurizes the liquid within the bladder.
- the pressurized liquid will constantly move the non-loaded parts of the bladder upwards. Movement or weight shift by the user will cause fluid movement, whereby a constant movement of the small internal foot muscles occurs.
- Considerably improved venous pump function is thereby established in the foot itself. A constant massage of the foot sole occurs for each time weight distribution is changed.
- Another effect of insufficient blood supply is a reduction of the contraction ability of the muscles.
- the fluid filled insole of the invention enhances the location, amount and duration of beneficial massage action.
- a positive effect is a reduction and in many instances elimination of the painful effect of soreness in feet, legs, neck, head, and back caused by standing or walking for many hours a day.
- the specific location of the flow deflectors in the metatarsal, heel and arch regions ensures correct circulation of liquid. This is important since uncontrolled liquid circulation would result in unstable walking and weight distribution.
- Directional stability in the liquid circulation ensures a flexible and symmetric walking, because the weight is resting on the foot's natural points.
- the function is similar to waterbeds. Obviously, the weight is the heaviest where one first places his foot on the ground, which is, logically, individual from person to person.
- the insole can help the problems involved in supination and pronation, i.e. where the user's feet are turning either to the inside or the outside ("asymmetric feet").
- the combination of dispersing of weight pressure and controlled fluid circulation also supports a functionally correct take-off; a factor crucial for walking or running in an physiologically correct manner.
- reflex zones appear under your feet, influencing various organs in your body. The therapy is performed by massaging the reflex zones. Examples of organs that are influenced are: kidneys, urinal system, sense organs, circulatory system, stomach, heart and metabolism.
- the insoles of the invention stimulate the reflex zones, and thus rectifies imbalances in vital functional areas of the body.
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
- Finger-Pressure Massage (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/264,447 US6138382A (en) | 1993-04-15 | 1999-03-08 | Fluid filled insole |
US09/265,044 US6092310A (en) | 1993-04-15 | 1999-03-08 | Fluid filled insole |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4768593A | 1993-04-15 | 1993-04-15 | |
US47685 | 1993-04-15 | ||
PCT/DK1994/000152 WO1994023603A1 (en) | 1993-04-15 | 1994-04-15 | Fluid filled insole |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0725580A1 true EP0725580A1 (en) | 1996-08-14 |
EP0725580B1 EP0725580B1 (en) | 2002-07-10 |
Family
ID=21950370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94914349A Expired - Lifetime EP0725580B1 (en) | 1993-04-15 | 1994-04-15 | Fluid filled insole |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0725580B1 (en) |
AT (1) | ATE220299T1 (en) |
AU (1) | AU6676694A (en) |
CA (1) | CA2160587A1 (en) |
DE (1) | DE69430956T2 (en) |
DK (1) | DK0725580T3 (en) |
WO (1) | WO1994023603A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4446252A1 (en) * | 1994-01-18 | 1995-06-22 | Klaus Peter Jaehnke | Instep for shoe, adaptable to foot |
IT242312Y1 (en) * | 1996-10-31 | 2001-06-04 | Mario Ambrosone | KINESIOLOGICAL FOOTBED WITH PROPRIOCEPTIVE FUNCTION AND REFLEXOGEN PEARL CORRECTION AT POSTURAL ADDRESS |
ATE207713T1 (en) | 1997-05-14 | 2001-11-15 | Hans Seiter | SHOE INSOLE |
IT1303333B1 (en) * | 1998-07-16 | 2000-11-06 | Bonis S P A | FOOTWEAR FOR FOOTWEAR. |
JP2000236908A (en) * | 1999-02-23 | 2000-09-05 | Himiko Co Ltd | Insole or outsole of shoe |
WO2002028216A1 (en) * | 2000-10-06 | 2002-04-11 | Vindriis Soeren | Shock absorbing and pressure reducing insole |
TW587013B (en) * | 2002-04-22 | 2004-05-11 | Jeng-Shian Ji | Method for making resilient shoe sole that comprises a stereoscopic contour integrally formed about a peripherey thereof |
DE10218987A1 (en) | 2002-04-24 | 2003-11-06 | Hans Seiter | Shoe insole for diabetics |
DE102014008513B4 (en) | 2014-06-03 | 2018-06-21 | Jan Siemers | Contact insert for soles |
USD828989S1 (en) | 2016-12-05 | 2018-09-25 | Protalus LLC | Insole |
USD859802S1 (en) | 2018-01-19 | 2019-09-17 | Protalus LLC | Insole |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4123855A (en) * | 1977-08-10 | 1978-11-07 | Thedford Shirley C | Fluid filled insole |
US4567677A (en) * | 1984-08-29 | 1986-02-04 | Pittsburgh Plastics Manufacturing | Water filled shoe insole |
-
1994
- 1994-04-15 EP EP94914349A patent/EP0725580B1/en not_active Expired - Lifetime
- 1994-04-15 DE DE69430956T patent/DE69430956T2/en not_active Expired - Fee Related
- 1994-04-15 AU AU66766/94A patent/AU6676694A/en not_active Abandoned
- 1994-04-15 AT AT94914349T patent/ATE220299T1/en not_active IP Right Cessation
- 1994-04-15 CA CA002160587A patent/CA2160587A1/en not_active Abandoned
- 1994-04-15 DK DK94914349T patent/DK0725580T3/en active
- 1994-04-15 WO PCT/DK1994/000152 patent/WO1994023603A1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
See references of WO9423603A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994023603A1 (en) | 1994-10-27 |
DE69430956D1 (en) | 2002-08-14 |
EP0725580B1 (en) | 2002-07-10 |
DK0725580T3 (en) | 2002-09-16 |
CA2160587A1 (en) | 1994-10-27 |
AU6676694A (en) | 1994-11-08 |
ATE220299T1 (en) | 2002-07-15 |
DE69430956T2 (en) | 2003-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5878510A (en) | Fluid filled insole | |
US6178663B1 (en) | Fluid filled insole with metatarsal pad | |
US6138382A (en) | Fluid filled insole | |
US6092310A (en) | Fluid filled insole | |
US4047310A (en) | Fatigue relieving foot appliance | |
US4674203A (en) | Inner part of shoe with a surface massaging the soles of the feet and process for its fabrication | |
EP0725580B1 (en) | Fluid filled insole | |
JP5187918B2 (en) | Foot pain relief / reduction / trouble solving shoes and insoles | |
KR101238618B1 (en) | Massaging and cushioning shoe insole | |
CN209547128U (en) | A kind of insole with traditional Chinese medicine slow-releasing healthcare function and the shoes comprising the insole | |
KR20050072411A (en) | Functional sole of shoe | |
CN201813958U (en) | Insole | |
DE69928629T2 (en) | Fluid filled insole | |
CN215189662U (en) | Medicine pad, medicine pad socks and medicine pad shoes | |
CN220800225U (en) | Insole capable of containing traditional Chinese medicine | |
CN215381836U (en) | Traditional chinese medicine device acupuncture point massage shoe-pad | |
WO1989000018A1 (en) | Inner sole | |
CN211268871U (en) | Diabetes foot nursing medicine physiotherapy pad | |
CN216059427U (en) | Physiotherapy insole for endocrine regulation and nursing | |
JP3032621U (en) | Insole structure of footwear | |
EP0803208A1 (en) | Insole | |
NO890875L (en) | INNERSAALE. | |
KR200390412Y1 (en) | Functional Shoes | |
CN2352005Y (en) | Health-care massage shoe pad | |
CN2146147Y (en) | Hypertension-lowering shoe-pad |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951110 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19970623 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SCHOESLER, HENNING RAUN |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SCHOESLER, HENNING RAUN |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020710 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020710 |
|
REF | Corresponds to: |
Ref document number: 220299 Country of ref document: AT Date of ref document: 20020715 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69430956 Country of ref document: DE Date of ref document: 20020814 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: TROESCH SCHEIDEGGER WERNER AG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20021010 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030415 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030415 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030430 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20030411 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20050323 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20050330 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20050425 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20050427 Year of fee payment: 12 Ref country code: NL Payment date: 20050427 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20050429 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20050527 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20050722 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060415 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060415 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060416 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061101 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061101 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20060415 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20061101 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20061230 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060502 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060430 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20090401 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100415 |